US20200085731A1 - Stable liquid formulations of melphalan - Google Patents

Stable liquid formulations of melphalan Download PDF

Info

Publication number
US20200085731A1
US20200085731A1 US16/694,331 US201916694331A US2020085731A1 US 20200085731 A1 US20200085731 A1 US 20200085731A1 US 201916694331 A US201916694331 A US 201916694331A US 2020085731 A1 US2020085731 A1 US 2020085731A1
Authority
US
United States
Prior art keywords
melphalan
propylene glycol
monothioglycerol
formulation
ethanol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US16/694,331
Inventor
Kocherlakota CHANDRASHEKHAR
Banda NAGARAJU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leiutis Pharmaceutials LLP
Original Assignee
Leiutis Pharmaceutials LLP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leiutis Pharmaceutials LLP filed Critical Leiutis Pharmaceutials LLP
Priority to US16/694,331 priority Critical patent/US20200085731A1/en
Publication of US20200085731A1 publication Critical patent/US20200085731A1/en
Assigned to LEIUTIS PHARMACEUTICALS PVT. LTD. reassignment LEIUTIS PHARMACEUTICALS PVT. LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHANDRASHEKHAR, KOCHERLAKOTA, NAGARAJU, BANDA
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids

Definitions

  • Melphalan also known as L-phenylalanine mustard, L-PAM, or L-sarcolysin is a phenylalanine derivative of nitrogen mustard.
  • Melphalan is a bifunctional alkylating agent that is active against selected human neoplastic diseases.
  • the molecular formula is C 13 H 18 C 12 N 2 O 2 and the molecular weight is 305.20.
  • the structural formula is:
  • U.S. Pat. No. 4,997,651 to Stephen et al. discloses two-component pharmaceutical formulation of Melphalan comprising freeze-dried Melphalan hydrochloride and a solvent-diluent comprising a citrate, propylene glycol and ethanol.
  • U.S patent application Nos. 2010/0311838, 2014/0213650 and 2014/0221488 disclose parenteral compositions comprising Melphalan and a cyclodextrin derivative.
  • RU2060031 discloses parenteral lyophilized formulation comprising a Melphalan, polyvinylpyrrolidone, ascorbic acid, glutamic acid, hydrochloric acid and D-mannitol.
  • injectable Alkeran® consists of two components comprising of Melphalan hydrochloride and polyvinylpyrrolidone lyophilized and a diluent comprising a mixture of sodium citrate, water for injection, propylene glycol and ethanol.
  • the Alkeran® to be infused must be diluted to not more than 0.45 mg/ml in normal saline and infused over 15 minutes.
  • One object of the invention provides ready to use liquid parenteral formulation of Melphalan.
  • Another aspect of the present invention is to provide ready to use liquid parenteral formulation comprising Melphalan, one or more solvents, anti-oxidants and other pharmaceutically acceptable adjuvants thereof.
  • Yet another aspect of the present invention provides method for preparing ready to use liquid parenteral formulation of Melphalan comprising Melphalan Hydrochloride, one or more solvents, anti-oxidants and other pharmaceutically acceptable adjuvants thereof.
  • Melphalan refers to the pharmaceutically acceptable salts, solvates, hydrates and anhydrous forms thereof, preferably Melphalan Hydrochloride.
  • melt-based Melphalan formulations refers to formulations that contain Melphalan in dissolved or solubilized form and are intended to be used as such or upon further dilution in intravenous diluents.
  • liquid parenteral formulations of Melphalan comprise
  • liquid parenteral formulations of Melphalan comprise
  • composition according to the present invention is intended to be stored at a temperature of 2-8° C.
  • Suitable solvents include, but are not limited to dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), N-methylpyrrolidone, dimethylisosorbide, ethanol, propylene glycol, glycerine, polyethylene alcohol, propylene glycol esters, polyethylene glycols and the like.
  • DMA dimethylacetamide
  • DMSO dimethyl sulfoxide
  • N-methylpyrrolidone dimethylisosorbide
  • ethanol propylene glycol
  • glycerine polyethylene alcohol
  • propylene glycol esters polyethylene glycols and the like.
  • Preferred solvents are dimethylacetamide (DMA), ethanol, polyethylene glycols (PEG), glycerine and propylene glycol.
  • compositions of the present invention also contain one or more anti-oxidants selected from the group, but not limited to butylated hydroxyanisole (BHA), butylated hydroxyl toluene (BHT), citric acid, lactic acid, benzoic acid, tocopherol (Vitamin E), ethylenediaminetetraacetic acid, sodium metabisulfite, sodium bisulfite, monothioglycerol, ascorbic acid and their esters, L-cysteine, parabens, benzyl alcohol, propyl gallate, thioglycolic acid, tartaric acid, phosphoric acid, gluconic acid, thiodipropionic acid, acetonic dicarboxylic acid, amino acids such as histidine, cysteine, tryptophan, tyrosine; chelating agents and the like. Most preferred anti-oxidant is monothioglycerol.
  • BHA butylated hydroxyanisole
  • BHT butylated
  • the formulation of the present invention may additionally contain buffers, pH adjusting agents, stabilizers such as, but not limited to citrate buffer, glutamate, dicarboxylic acid, lecithin, di(hydroxyethyl)glycine, sorbitol, bicarbonate, tartrate, benzoate, lactate, gluconate, glycine, TRIS buffer, acetate buffer, boric acid buffer, phosphate buffer, amino acids, meglumine and the like.
  • buffers pH adjusting agents
  • stabilizers such as, but not limited to citrate buffer, glutamate, dicarboxylic acid, lecithin, di(hydroxyethyl)glycine, sorbitol, bicarbonate, tartrate, benzoate, lactate, gluconate, glycine, TRIS buffer, acetate buffer, boric acid buffer, phosphate buffer, amino acids, meglumine and the like.
  • liquid parenteral formulations of Melphalan comprise:
  • the invention further relates to a process of preparing liquid formulations of Melphalan.
  • the process comprises:
  • liquid pharmaceutical formulation of Melphalan comprising of one or more solvents selected form DMA, Ethanol, PEG and propylene glycol in the presence of an anti-oxidant yields a stable liquid formulation of Melphalan overcoming the disadvantages associated with prior art.
  • Melphalan Hydrochloride was added to the manufacturing vessel containing N, N, Dimethyl acetamide and ethanol and stirred to get a clear solution.
  • Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution.
  • the obtained solution was filtered and filled in vials followed by capping and sealing.
  • Melphalan Hydrochloride was added to the manufacturing vessel containing N,N,dimethyl acetamide and ethanol and stirred to get a clear solution.
  • Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution.
  • the obtained solution was filtered and filled in vials followed by capping and sealing.
  • Melphalan Hydrochloride was added to the manufacturing vessel containing polyethylene glycol and ethanol and stirred to get a clear solution.
  • Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution.
  • the obtained solution was filtered and filled in vials followed by capping and sealing.
  • Melphalan Hydrochloride was added to the manufacturing vessel containing polyethylene glycol. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.
  • Melphalan Hydrochloride was added to the manufacturing vessel containing polyethylene glycol. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.

Abstract

The present invention relates to stable, liquid parenteral formulations of Melphalan or pharmaceutically acceptable salts thereof. Further this invention also describes process of preparing such formulations.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application is a U.S. National Phase filing under 35 U.S.C. § 371 of International Application PCT/IB2016/053881, filed Jun. 29, 2016, and published as WO 2017/002030 A1 on Jan. 5, 2017. PCT/IB2016/053881 claims priority from Indian application number 3328/CHE/2015, filed Jun. 30, 2015. The entire contents of each of these applications are hereby incorporated herein by reference.
    • BACKGROUND OF THE INVENTION
  • Melphalan, also known as L-phenylalanine mustard, L-PAM, or L-sarcolysin is a phenylalanine derivative of nitrogen mustard. Melphalan is a bifunctional alkylating agent that is active against selected human neoplastic diseases. The molecular formula is C13H18C12N2O2 and the molecular weight is 305.20. The structural formula is:
  • Figure US20200085731A1-20200319-C00001
  • U.S. Pat. No. 4,997,651 to Stephen et al., discloses two-component pharmaceutical formulation of Melphalan comprising freeze-dried Melphalan hydrochloride and a solvent-diluent comprising a citrate, propylene glycol and ethanol.
  • U.S patent application No. 2013/0131174 to Castillo et al., discloses a solid lyophilized composition of Melphalan hydrochloride having a pH between 4 and 6.
  • U.S patent application Nos. 2010/0311838, 2014/0213650 and 2014/0221488 disclose parenteral compositions comprising Melphalan and a cyclodextrin derivative.
  • RU2060031 discloses parenteral lyophilized formulation comprising a Melphalan, polyvinylpyrrolidone, ascorbic acid, glutamic acid, hydrochloric acid and D-mannitol.
  • The commercial formulation of injectable Alkeran® consists of two components comprising of Melphalan hydrochloride and polyvinylpyrrolidone lyophilized and a diluent comprising a mixture of sodium citrate, water for injection, propylene glycol and ethanol.
  • The Alkeran® to be infused must be diluted to not more than 0.45 mg/ml in normal saline and infused over 15 minutes.
  • The reconstitution of the lyophilized product is clinically inconvenient and the lyophilization process is time consuming and often incurs significant expense. Hence, there is a strong need to develop alternate formulations of Melphalan.
  • The inventors have developed ready to use liquid formulation of Melphalan which overcomes the disadvantages of the formulations reported in prior art.
    • SUMMARY OF THE INVENTION
  • One object of the invention provides ready to use liquid parenteral formulation of Melphalan.
  • Another aspect of the present invention is to provide ready to use liquid parenteral formulation comprising Melphalan, one or more solvents, anti-oxidants and other pharmaceutically acceptable adjuvants thereof.
  • Yet another aspect of the present invention provides method for preparing ready to use liquid parenteral formulation of Melphalan comprising Melphalan Hydrochloride, one or more solvents, anti-oxidants and other pharmaceutically acceptable adjuvants thereof.
    • DETAILED DESCRIPTION OF THE INVENTION
  • In the context of this invention “Melphalan” refers to the pharmaceutically acceptable salts, solvates, hydrates and anhydrous forms thereof, preferably Melphalan Hydrochloride.
  • As used herein, “ready to use” Melphalan formulations refers to formulations that contain Melphalan in dissolved or solubilized form and are intended to be used as such or upon further dilution in intravenous diluents.
  • In one embodiment, ready to use liquid parenteral formulations of Melphalan comprise
  • i. Melphalan,
  • ii. one or more solvents,
  • iii. anti-oxidants,
  • optionally other pharmaceutically acceptable adjuvants thereof.
  • In yet another embodiment, ready to use liquid parenteral formulations of Melphalan comprise
      • i. Melphalan Hydrochloride,
      • ii. one or more solvents selected from the group comprising of dimethylacetamide, polyethylene glycol, ethanol, propylene glycol and glycerine,
      • iii. anti-oxidants selected from monothioglycerol, L-cysteine, ascorbic acid and optionally other pharmaceutically acceptable adjuvants thereof.
  • The composition according to the present invention is intended to be stored at a temperature of 2-8° C.
  • Suitable solvents include, but are not limited to dimethylacetamide (DMA), dimethyl sulfoxide (DMSO), N-methylpyrrolidone, dimethylisosorbide, ethanol, propylene glycol, glycerine, polyethylene alcohol, propylene glycol esters, polyethylene glycols and the like. Preferred solvents are dimethylacetamide (DMA), ethanol, polyethylene glycols (PEG), glycerine and propylene glycol.
  • The pharmaceutical compositions of the present invention also contain one or more anti-oxidants selected from the group, but not limited to butylated hydroxyanisole (BHA), butylated hydroxyl toluene (BHT), citric acid, lactic acid, benzoic acid, tocopherol (Vitamin E), ethylenediaminetetraacetic acid, sodium metabisulfite, sodium bisulfite, monothioglycerol, ascorbic acid and their esters, L-cysteine, parabens, benzyl alcohol, propyl gallate, thioglycolic acid, tartaric acid, phosphoric acid, gluconic acid, thiodipropionic acid, acetonic dicarboxylic acid, amino acids such as histidine, cysteine, tryptophan, tyrosine; chelating agents and the like. Most preferred anti-oxidant is monothioglycerol.
  • The formulation of the present invention may additionally contain buffers, pH adjusting agents, stabilizers such as, but not limited to citrate buffer, glutamate, dicarboxylic acid, lecithin, di(hydroxyethyl)glycine, sorbitol, bicarbonate, tartrate, benzoate, lactate, gluconate, glycine, TRIS buffer, acetate buffer, boric acid buffer, phosphate buffer, amino acids, meglumine and the like.
  • Solubility studies were carried out with various solvents at 25° C. temperature, to check the solubility of Melphalan hydrochloride. The data is summarized in table 1:
  • TABLE 1
    Solubility studies in various solvents
    Quantity of solvents
    Qty of Melphalan PEG- Propylene
    Hydrochloride DMA 400 Glycol Ethanol Result
    100 mg 1.1 mL — — — Clear
    100 mg 0.5 mL — —  0.5 mL Clear
    100 mg — —   1 mL — Not Clear
    100 mg — — —   1 mL Hazy
    solution
    100 mg 0.3 mL — 0.05 mL  0.65 mL Clear
    100 mg — 1.0 mL   0 mL — Clear after
    vigorous
    mixing
    100 mg — 0.9 mL 0.1 mL — Clear
    100 mg — 0.7 mL 0.3 mL — Clear
    100 mg — 0.5 mL 0.5 mL — Clear
    100 mg — 0.2 mL 0.8 mL — Clear
    100 mg — 0.1 mL 0.9 mL — Clear
  • In one of the preferred embodiment, ready to use liquid parenteral formulations of Melphalan comprise:
  •
    i. Melphalan Hydrochloride 1 to 30%
    ii. dimethylacetamide or polyethylene glycol 20 to 95%
    iii. ethanol 0 to 50%
    iv. propylene glycol. 5 to 50%
    v. monothioglycerol 0.05 to 5%

    by weight of the composition.
  • The invention further relates to a process of preparing liquid formulations of Melphalan. The process comprises:
      • i. Addition of Melphalan to the manufacturing vessel containing solvent and stirred till a clear solution is obtained.
      • ii. Addition of remaining solvents to the above solution and stirred.
      • iii. Addition of anti-oxidant to the solution and stirred till a homogenous solution is obtained.
      • iv. Filtering and filling the solution in to suitable containers or vials.
  • Melphalan formulation prepared according to the invention was tested for stability at various stability conditions such as 2-8° C. and 25° C./60% RH for a period of 6 months. Stability data is summarized in table 2.
  • TABLE 2
    Stability data for the product obtained from Example 5
    Condition
    2-8° C. 25° C./60% RH
    Time point
    Initial 1 M 3 M 6 M 1 M 3 M 6 M
    Assay By HPLC (%) 99.2 97.8 97.7 96.8 97.2 94.0 90.1
    Total Impurities 0.17 0.24 0.32 0.75 0.89 2.26 4.33
    (% w/w)
  • Surprisingly no significant increase in total impurities was observed even at 25° C./65% RH. The inventors have found that liquid pharmaceutical formulation of Melphalan comprising of one or more solvents selected form DMA, Ethanol, PEG and propylene glycol in the presence of an anti-oxidant yields a stable liquid formulation of Melphalan overcoming the disadvantages associated with prior art.
  • Comparative dilution studies were performed to check the stability of the diluted formulations. Melphalan formulation prepared according to the invention was diluted with 0.9% NaCl to get concentration of 0.45 mg/mL. Alkeran® vial (Batch No: P283) was considered as reference for comparative dilution study. Stability of the diluted product was studied at 0 minutes, 30 mins and 60 min. The stability data of the invention formulation and reference product is summarized in table 3.
  • TABLE 3
    Comparative dilution study of the invention formulation with
    reference product Dilution study with 0.9% NaCl
    Formulation
    Reference product
    Invention formulation after reconstitution with
    after dilution with diluent, followed by
    0.9% NaCl dilution with 0.9% NaCl
    Time point
    Initial 30 min 60 min Initial 30 min 60 min
    Assay (%) 97.3 97.6 95.2 95.6 91.1 88.2
    pH of Solution 3.51 3.48 3.48 5.83 6.06 6.35
    Osmolality 352 348 354 1120 1119 1122
    (mOsm/kg)
    Related
    Substances Impurities % (w/w)
    Impurity D 1.23 3.31 5.35 1.11 3.67 5.73
    Impurity G 0.14 0.15 0.17 0.49 0.52 0.51
    Total 1.6 3.8 5.8 1.94 5.08 7.65
    Impurities
  • Surprisingly Melphalan formulation prepared according to the invention showed better stability profile compared to the reference product.
  • The following examples further describe certain specific aspects and embodiments of the present invention and demonstrate the practice and advantages thereof.
    • Example 1
  • Qty/vial
    Ingredients (mg)
    Melphalan Hydrochloride  20-200
    N,N,Dimethyl acetamide 350-490
    Ethanol 200-280
    Propylene glycol 180-270
    Monothioglycerol 3-8
    • Manufacturing Process
  • Melphalan Hydrochloride was added to the manufacturing vessel containing N, N, Dimethyl acetamide and ethanol and stirred to get a clear solution. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.
  • Melphalan formulation prepared according to the invention was tested for stability at various stability conditions such as 2-8° C. and 25° C./60% RH for a period of 6 months. Stability data is summarized in table 4.
  • TABLE 4
    Stability data for the product obtained from Example 1
    Condition
    2-8° C. 25° C.
    Time point
    Initial 1 M 3 M 6 M 1 M 3 M 6 M
    Assay By 100.3 100.3 103.3 98.3 99.5 101.1 94.4
    HPLC (%)
    Total 0.19 0.16 0.20 0.63 0.30 1.60 4.37
    impurities
    *RRT: Relative Retention Time
    • Example 2
  • Qty/vial Qty/vial Qty/vial
    Ingredients (mg) (mg) (mg)
    Melphalan 20-200 20-200 20-200
    Hydrochloride
    N, N, Dimethyl 380 380 380
    acetamide
    Ethanol 240 320 280
    Propylene glycol 310 210 260
    Monothioglycerol 2.53 5.05 5.05
    • Manufacturing Process
  • Melphalan Hydrochloride was added to the manufacturing vessel containing N,N,dimethyl acetamide and ethanol and stirred to get a clear solution. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.
    • Example 3
  • Qty/vial
    Ingredients (mg)
    Melphalan Hydrochloride 20-200
    Polyethylene glycol 570
    Ethanol 240
    Propylene glycol 210
    Monothioglycerol 5.05
    • Manufacturing Process
  • Melphalan Hydrochloride was added to the manufacturing vessel containing polyethylene glycol and ethanol and stirred to get a clear solution. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.
    • Example 4
  • Quantity/vial
    Ingredients (mg)
    Melphalan Hydrochloride  20-200
    Polyethylene glycol-400 490-620
    Propylene glycol 320-390
    Monothioglycerol 5.05
    • Manufacturing Process
  • Melphalan Hydrochloride was added to the manufacturing vessel containing polyethylene glycol. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.
    • Example 5
  • Quantity/vial
    Ingredients (mg)
    Melphalan Hydrochloride  20-200
    Polyethylene glycol-400 590-950
    Propylene glycol 120-420
    Monothioglycerol 5-8
    • Manufacturing Process
  • Melphalan Hydrochloride was added to the manufacturing vessel containing polyethylene glycol. Propylene glycol was added, followed by the addition of monothioglycerol and stirred to get homogenous solution. The obtained solution was filtered and filled in vials followed by capping and sealing.

Claims (8)

1. (canceled)
2: The formulation of claim 3, wherein the pH of the formulation is between 2 to 5.
3: A stable, liquid parenteral formulation consisting essentially of:
(i) Melphalan
(ii) one or more solvents and
(iii) one or more anti-oxidants.
4: A stable, liquid parenteral formulation consisting essentially of:
(i) Melphalan hydrochloride
(ii) one or more solvents selected from dimethyl acetamide, polyethylene glycol, ethanol, propylene glycol and glycerine.
(iii) anti-oxidants selected from monothioglycerol, L-cysteine and chelating agents.
5. (canceled)
6: The stable, liquid parenteral formulation of claim 4 consisting of:
(i) Melphalan hydrochloride 1 to 30% (ii) dimethylacetamide 20 to 85% (iii) ethanol 0 to 50% (iv) propylene glycol 5 to 50% (v) at least one of monothioglycerol, chelating agent, 0.05 to 5% and both in combination by weight of the composi- tion.
7: The stable, liquid parenteral formulation of claim 4 consisting of:
(i) Melphalan hydrochloride 1 to 30% (ii) polyethylene glycol 20 to 85% (iii) ethanol 0 to 50% (iv) propylene glycol 5 to 50% (v) at least one of monothioglycerol, chelating agent, 0.05 to 5% and both in combination by weight of the composi- tion.
8: A stable, liquid parenteral formulation of Melphalan consisting essentially of:
(i) Melphalan hydrochloride 1 to 30% (ii) polyethylene glycol 20 to 85% (iii) propylene glycol 5 to 50% (iv) monothioglycerol 0.05 to 5% (v) chelating agent by weight of the composition. 0.01 to 5%
US16/694,331 2015-06-30 2019-11-25 Stable liquid formulations of melphalan Abandoned US20200085731A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/694,331 US20200085731A1 (en) 2015-06-30 2019-11-25 Stable liquid formulations of melphalan

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN3328/CHE/2015 2015-06-30
IN3328CH2015 2015-06-30
PCT/IB2016/053881 WO2017002030A1 (en) 2015-06-30 2016-06-29 Stable liquid formulations of melphalan
US201715739034A 2017-12-21 2017-12-21
US16/694,331 US20200085731A1 (en) 2015-06-30 2019-11-25 Stable liquid formulations of melphalan

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/IB2016/053881 Continuation WO2017002030A1 (en) 2015-06-30 2016-06-29 Stable liquid formulations of melphalan
US15/739,034 Continuation US10537520B2 (en) 2015-06-30 2016-06-29 Stable liquid formulations of melphalan

Publications (1)

Publication Number Publication Date
US20200085731A1 true US20200085731A1 (en) 2020-03-19

Family

ID=57608004

Family Applications (2)

Application Number Title Priority Date Filing Date
US15/739,034 Active US10537520B2 (en) 2015-06-30 2016-06-29 Stable liquid formulations of melphalan
US16/694,331 Abandoned US20200085731A1 (en) 2015-06-30 2019-11-25 Stable liquid formulations of melphalan

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US15/739,034 Active US10537520B2 (en) 2015-06-30 2016-06-29 Stable liquid formulations of melphalan

Country Status (2)

Country Link
US (2) US10537520B2 (en)
WO (1) WO2017002030A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017002030A1 (en) * 2015-06-30 2017-01-05 Leiutis Pharmaceuticals Pvt Ltd Stable liquid formulations of melphalan
US20210145778A1 (en) * 2018-01-01 2021-05-20 Orbicular Pharmaceutical Technologies Pvt. Ltd. Stable Liquid Compositions of Melphalan
ES2928931T3 (en) 2018-03-29 2022-11-23 Project Pharmaceutics Gmbh liquid pharmaceutical formulation
US10682326B1 (en) 2019-06-03 2020-06-16 Shilpa Medicare Limited Stable melphalan liquid injectable formulations
EP4055005A4 (en) * 2019-11-04 2023-11-29 Intas Pharmaceuticals Ltd. Liquid melphalan composition
US11857677B2 (en) * 2019-12-19 2024-01-02 Rk Pharma Inc. Ready to use injectable formulations of melphalan and processes for preparation thereof
WO2024011169A1 (en) * 2022-07-06 2024-01-11 Good Health, Llc Stable, liquid pharmaceutical compositions comprising melphalan

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317281A2 (en) * 1987-11-19 1989-05-24 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
US20090098209A1 (en) * 2007-10-15 2009-04-16 University Of Kansas Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
US20100311838A1 (en) * 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards
US20170020177A1 (en) * 2013-11-29 2017-01-26 Kewpie Corporation Acidic oil-in-water type emulsified condiment
US20180193255A1 (en) * 2015-06-30 2018-07-12 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2060031C1 (en) 1993-05-27 1996-05-20 Онкологический научный центр Method of sarcolysin preparing for intravenous injection
US6805786B2 (en) * 2002-09-24 2004-10-19 Northrop Grumman Corporation Precious alloyed metal solder plating process
US7988992B2 (en) * 2006-07-06 2011-08-02 KOS Life Sciences Abbott Laboratories Superporous hydrogels for heavy-duty applications
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
WO2012094020A1 (en) * 2010-01-07 2012-07-12 Innopharma, Inc. Methods and compositions for delivery of taxanes in stable oil-in-water emulsions
AR077384A1 (en) 2010-07-05 2011-08-24 Eriochem Sa AN INJECTABLE PHARMACEUTICAL FORMULATION OF MELFALANO.
UA119324C2 (en) * 2013-04-02 2019-06-10 Теміс Медікер Лімітед Compositions of pharmaceutical actives containing diethylene glycol monoethyl ether or other alkyl derivatives

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0317281A2 (en) * 1987-11-19 1989-05-24 The Wellcome Foundation Limited Pharmaceutical formulations containing melphalan or melphalan hydrochloride, as well as melphalan and melphalan hydrochloride and processes for preparing them
US20090098209A1 (en) * 2007-10-15 2009-04-16 University Of Kansas Pharmaceutical compositions containing water-soluble derivatives of propofol and methods of administering same via pulmonary administration
US20100311838A1 (en) * 2009-05-29 2010-12-09 Pipkin James D Injectable Melphalan Compositions Comprising a Cyclodextrin Derivative and Methods of Making and Using the Same
US20140005148A1 (en) * 2012-06-29 2014-01-02 Coldstream Laboratories Inc. Stable liquid formulations of nitrogen mustards
US20170020177A1 (en) * 2013-11-29 2017-01-26 Kewpie Corporation Acidic oil-in-water type emulsified condiment
US20180193255A1 (en) * 2015-06-30 2018-07-12 Leiutis Pharmaceuticals Pvt. Ltd. Stable liquid formulations of melphalan

Also Published As

Publication number Publication date
WO2017002030A1 (en) 2017-01-05
US20180193255A1 (en) 2018-07-12
US10537520B2 (en) 2020-01-21

Similar Documents

Publication Publication Date Title
US10537520B2 (en) Stable liquid formulations of melphalan
US20140206733A1 (en) Liquid Formulations Of Bendamustine
US10864250B2 (en) Formulations of vancomycin
JP6736765B2 (en) Bendamustine solution formulation
US9603930B2 (en) Liquid bendamustine formulation
US20210220375A1 (en) Stable ready to use cyclophosphamide liquid formulations
US20190151234A1 (en) Stable liquid pharmaceutical formulations of bendamustine
US20180071393A1 (en) Stable intravenous formulation
US20240009198A1 (en) Pemetrexed formulations
WO2016005995A2 (en) Glycol free stable liquid compositions of bendamustine
US20100010214A1 (en) Lyophilized preparation of 1-methylcarbapenem
US11058745B1 (en) Stable liquid pharmaceutical compositions of daptomycin
US20190224202A1 (en) Stable liquid formulations of pemetrexed
WO2019130228A1 (en) Stable liquid compositions of melphalan
US20190070136A1 (en) Parenteral compositions of carmustine
US10682326B1 (en) Stable melphalan liquid injectable formulations
US7687516B2 (en) Alcohol free formulation of argatroban
US11826466B2 (en) Bendamustine solution formulations
EP4055005A1 (en) Liquid melphalan composition
WO2024009319A1 (en) Liquid injectable compositions of trilaciclib
AU2016393213A1 (en) Pemetrexed formulations

Legal Events

Date Code Title Description
AS Assignment

Owner name: LEIUTIS PHARMACEUTICALS PVT. LTD., INDIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANDRASHEKHAR, KOCHERLAKOTA;NAGARAJU, BANDA;REEL/FRAME:052246/0921

Effective date: 20180116

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION